A Phase 2 Study With CC-220 in Skin Sarcoidosis

NCT02192489 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Administrative

Conditions

Sarcoidosis

Interventions

DRUG: CC-220 0.3 mg Daily
DRUG: CC-220 0.6mg Daily
DRUG: Placebo

Sponsor

Celgene